bimekizumab vs sonelokimab

NCT03370133 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo- and active-controlled phase 3 trial involving 567 participants. Both prespecified clinical skin endpoints at week 16—PASI90 and Investigator’s Global Assessment response—were significantly better with bimekizumab than with placebo and ustekinumab (all p<0.001).

NCT03384745 · Phase 2 · completed

This was a well-powered, randomized, blinded, placebo-controlled trial using a validated skin-clearance measure as its primary endpoint, and every sonelokimab dose group achieved a substantially and statistically significantly higher clear/almost-clear skin rate than placebo at week 12.

NCT03370133 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo- and active-controlled phase 3 trial involving 567 participants. Both prespecified clinical skin endpoints at week 16—PASI90 and Investigator’s Global Assessment response—were significantly better with bimekizumab than with placebo and ustekinumab (all p<0.001).

NCT05640245 · Phase 2 · completed

The study randomized 207 participants and used triple blinding with both placebo and active adalimumab comparator arms. Its primary endpoint was the clinical ACR50 response at week 12. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.